The 3-monthly depot LHRH-agonist leuprorelin acetate is an effective adjuvant treatment in premenopausal patients with hormone receptor-positive, node-positive breast cancer that is not inferior to CMF.
No takes yet. Share an insight, caveat, or question.
Schmid et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: